Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Interest Expenses (2016 - 2025)

Ironwood Pharmaceuticals' Interest Expenses history spans 16 years, with the latest figure at $7.9 million for Q4 2025.

  • For Q4 2025, Interest Expenses fell 11.53% year-over-year to $7.9 million; the TTM value through Dec 2025 reached $32.7 million, down 0.87%, while the annual FY2025 figure was $32.7 million, 0.87% down from the prior year.
  • Interest Expenses for Q4 2025 was $7.9 million at Ironwood Pharmaceuticals, down from $8.4 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $9.8 million in Q3 2023 and bottomed at $1.5 million in Q3 2022.
  • The 5-year median for Interest Expenses is $7.8 million (2021), against an average of $6.3 million.
  • The largest annual shift saw Interest Expenses crashed 80.81% in 2022 before it surged 545.6% in 2023.
  • A 5-year view of Interest Expenses shows it stood at $8.0 million in 2021, then plummeted by 80.81% to $1.5 million in 2022, then skyrocketed by 451.97% to $8.4 million in 2023, then increased by 5.83% to $8.9 million in 2024, then dropped by 11.53% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Interest Expenses are $7.9 million (Q4 2025), $8.4 million (Q3 2025), and $8.4 million (Q2 2025).